AVI Biopharma Inc.

avi biopharma inc. - All News and Analysis

• AVI BioPharma, Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-08-11

  Question-and-Answer SessionOperator Thank you. Operator instructions. Michael Hubbard Given that we have no questions currently, we thank you all for participating and I’ll turn it over once again for final comments by Dr. Hudson. Dr. Leslie Hudson Well, thank you for listening. We had quite a number of callers...

  Tags: AVI Biopharma Inc.

• AVI BioPharma, Inc.Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-03-12

  Question-and-Answer SessionOperator Thank you. Operator Instructions One moment please for the first question. Your first question comes from the line of Ren Benjamin of Rodman and Renshaw. Ren Benjamin- Rodman & Renshaw Llc Hi, good morning and thanks for taking the question. I guess just starting...

  Tags: AVI Biopharma Inc.

• AVI Biopharma Q3 2005 Earnings Conference Call Transcript (AVII)

  Seeking Alpha - 2005-11-04

  Earnings Call Excerpt Third Quarter 2005 Financial Results Conference Call Transcript Moderator: Denis Burger November 4, 2005 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2005 Third Quarter Financial Results conference call. At this time all participants are in a...

  Tags: AVI Biopharma Inc.

• BWR initiates research on AVI BioPharma Inc.

  - 2004-10-29

  M2 PRESSWIRE-29 October 2004-bellwetherreport.com: BWR initiates research on AVI BioPharma IncC1994-2004 M2 COMMUNICATIONS LTD RDATE:10292004 Bellwether Report issues aggressive investor alert for AVI Biopharma Inc (Nasdaq:AVII), an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon...

  Tags: AVI Biopharma Inc., FINANCE, Massachusetts Institute of Technology

Additional Resources

• BenchmarkJournal.com (Complimentary) Analyst Review for FRED, EXAR, NSANY and AVII

  - 2008-12-24

  Benchmark Journal brings independent company andsector research together, utilizing top financial advisors and investmenttactics to provide you with a clear picture of investment opportunities.Once you register as a free member to www.benchmarkjournal.com , you will begranted full access to our site, including sector analysis and companyanalysis. Our company profiles...

• Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII)bought Shares of Multiple Insiders.

  - 2008-03-27

  M2 PRESSWIRE-27 March 2008-InsiderCow.com: Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII)bought Shares of Multiple InsidersC1994-2008 M2 COMMUNICATIONS LTD RDATE:27032008 Reported by InsiderCow.com at 2008-03-26 15:42:37 ET Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII) bought 300,400...

• AVI Biopharma, Inc. Review in Progress.

  - 2008-03-25

  M2 PRESSWIRE-25 March 2008-Street Tips: AVI Biopharma, Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:25032008 Streetinvesting.com has now resumed our progressive review of AVI Biopharma, Inc. (NASDAQ:AVII) as it opened up $0.03 nearing its 52 week low of $1.00...

• (AVII) SqueezeTrigger Price is $5.061. There is $219,654,080.00 That Short Sellers Still Need To Cover.

  - 2008-03-06

  M2 PRESSWIRE-6 March 2008-BUYINS.NET: AVII SqueezeTrigger Price is $5.061. There is $219,654,080.00 That Short Sellers Still Need To CoverC1994-2008 M2 COMMUNICATIONS LTD RDATE:05032008 BUYINS.NET / www.squeezetrigger.com is monitoring AVI BIOPHARMA INC (NASDAQ:AVII) in real time and just received an...

• AVI BioPharma Completes Purchase of Building for GMP Manufacturing

  - 2007-04-20

  PORTLAND, Ore. -- Fourth graph, second complete sentence should read: AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. (sted: AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease.) The corrected...

• In- Depth Research on AVI Biopharma Inc.

  - 2007-04-11

  M2 PRESSWIRE-11 April 2007-Biotech News: In- Depth Research on AVI Biopharma IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:11042007 In- Depth Research on AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on...

• Shareholders alert for AVI Biopharma Inc.

  - 2007-04-02

  M2 PRESSWIRE-2 April 2007-Biotech News: Shareholders alert for AVI Biopharma IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:02042007 Shareholders alert for AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense...

• AVI Biopharma Inc. Announces Full Year and Fourth Quarter Results.

  - 2007-03-15

  M2 PRESSWIRE-15 March 2007-International Stock Targets: AVI Biopharma Inc. Announces Full Year and Fourth Quarter ResultsC1994-2007 M2 COMMUNICATIONS LTD RDATE:15032007 AVI Biopharma Inc. (Nasdaq:AVII) was down 4.44 today on just over 240,000 shares traded. AVI BioPharma, Inc. today...

• Obama denies knowing details of investments

  - 2007-03-08

  WASHINGTON AP -- Democratic presidential candidate Barack Obama said Wednesday he was not aware he had invested in two companies backed by some of his top donors and said he had done nothing to aid their business with the government. The Illinois senator faced questions about more...

• Investor Alert for Shareholders of AVI Biopharma Inc.

  - 2006-12-04

  M2 PRESSWIRE-4 December 2006-Biotech News: Investor Alert for Shareholders of AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:04122006 Investor Alert for Shareholders of AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart...

• Fundamental Review for AVI Biopharma Inc.

  - 2006-11-10

  M2 PRESSWIRE-10 November 2006-Biotech News: Fundamental Review for AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:10112006 Fundamental Review for AVI Biopharma Inc (NASDAQ: AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart disease. Its lead...

• Bellwether Report.com Acknowledges AVI Biopharma Inc.

  - 2006-10-19

  M2 PRESSWIRE-19 October 2006-bellwetherreport.com: Bellwether Report.com Acknowledges AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:19102006 The Bellwether Report Takes Notice of AVI Biopharma Inc (Nasdaq:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart...

• Bellwether Report.com Wants Your Attention Directed to AVI Biopharma Inc.

  - 2006-09-29

  M2 PRESSWIRE-29 September 2006-bellwetherreport.com: Bellwether Report.com Wants Your Attention Directed to AVI Biopharma Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:29092006 Bellwether Report Takes Notice of AVI Biopharma Inc. (NASDAQ:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer...

• AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.

  - 2006-09-01

  AVI BioPharma, Inc. (Nasdaq:AVII), Portland, Ore., announced today that it has entered patients to fill two new cohorts to extend the duration of treatment with AVI-4065 in its hepatitis C virus HCV clinical trial. One cohort will be treated twice daily for 28 days and the...

• Auriga Executes Strategic Alliance with Degussa Targeting Chronic Gastro-Intestinal Diseases.

  - 2006-08-23

  M2 PRESSWIRE-23 August 2006-InvestSource Inc.: Auriga Executes Strategic Alliance with Degussa Targeting Chronic Gastro-Intestinal DiseasesC1994-2006 M2 COMMUNICATIONS LTD RDATE:23082006 Stocks in the News: Auriga LaboratoriesTM, Inc. (OTC: ARGA), Alexza Pharmaceuticals Inc. (NASDAQ: ALXA), Valeant Pharmaceuticals International (NYSE: VRX), AVI Biopharma...

• Bellwether Report.com is Doing Due Diligence on AVI Biopharma Inc.

  - 2006-08-21

  M2 PRESSWIRE-21 August 2006-bellwetherreport.com: Bellwether Report.com is Doing Due Diligence on AVI Biopharma Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:21082006 The Bellwether Report Takes Notice of AVI Biopharma Inc. (Nasdaq:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments...

• Incorporated: 1980
• CEO: Dr. Leslie Hudson Ph.D.